| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Mosunetuzumab manufacturers
- Mosunetuzumab
-
- $228.00
-
2026-07-27
- CAS:1905409-39-3
- Purity: SDS-PAGE:94.4%;SEC-HPLC:96.1%
- Supply Ability: 10g
|
| | Mosunetuzumab Basic information |
| Product Name: | Mosunetuzumab | | Synonyms: | Mosunetuzumab;Mosunetuzumab (DHC90716);Research Grade Mosunetuzumab(DHC90716);Research Grade Mosunetuzumab;BTCT-4465A | | CAS: | 1905409-39-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Mosunetuzumab Structure]() |
| | Mosunetuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Mosunetuzumab Usage And Synthesis |
| Uses | Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1][2]. | | References | [1] Lihua E Budde, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491. DOI:10.1200/JCO.21.00931
[2] Gregory Z Ferl, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11(3):296-304. DOI:10.1111/cts.12535 |
| | Mosunetuzumab Preparation Products And Raw materials |
|